Saniona has announced a partnership with Acadia Pharmaceuticals to develop and commercialize SAN711. The total potential deal size is USD 610 million, including an upfront payment of USD 28 million—almost mirroring Saniona’s market value before the announcement. BioStock reached out to CEO Thomas Feldthus for a comment.
Read the full interview with Thomas Feldthus at biostock.se:
https://www.biostock.se/en/2024/11/sanionas-ceo-the-deal-with-acadia-is-significant/
This is a press release from BioStock – Connecting Innovation & Capital. https://www.biostock.se/
